P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the phase 1 study NCT02013219, the ORR of erlotinib plus atezolizumab was 75% in the expansion-stage group.
“The ORR of combination therapy was as high as 75% in the expansion-stage group”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [190]
In NCT02013219, tumor-infiltrating CD8+ T cells increased in 8/13 paired biopsies after 7-day erlotinib treatment.
“tumor-infiltrating CD8+ T cell was increased in 8/13 paired biopsies after 7-day erlotinib treatment [190].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [190]
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
“No pneumonitis and dose-limiting toxicity were reported in this study [190].”
BackgroundInfluentialSevere immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406 · see citing works
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342 · see citing works
Su, S., Dong, Z., Xie, Z., Yan, L., Li, Y., Su, J., Liu, S. M., Yin, K., Chen, R., Huang, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.016 · Cited by 141 · see citing works
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136 · see citing works
Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
Li, X., Lian, Z., Wang, S., Xing, L., & Yu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.005 · Cited by 96 · see citing works
Wang, H., Li, S., Wang, Q., Jin, Z., Shao, W., Gao, Y., Li, L., Lin, K., Zhu, L., Wang, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd7851 · Cited by 85 · see citing works
“Known combinations of the checkpoint inhibitors explored to date include those with (i) other immune checkpoint inhibitors (8), (ii) chemotherapy (9), and (iii) targeted therapies (10, 11).”
BackgroundThe combination of checkpoint immunotherapy and targeted therapy in cancer
Karachaliou, N., Gonzalez-Cao, M., Sosa, A. E., Berenguer, J., Bracht, J. W. P., Ito, M., & Rosell, R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.47 · Cited by 70 · see citing works
“gov number NCT02013219) that evaluates the safety and pharmacology of atezolizumab administered with erlotinib or alectinib in patients with advanced NSCLC are available (36).”
BackgroundInfluentialBerghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 54 · see citing works
Besse, B., Garrido, P., Cortot, A. B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.003 · Cited by 18 · see citing works
Self-citationCheckpoint Inhibitor Combined With Tyrosine Kinase Inhibitor—the End or Beginning?
Huang, D. D.-R., & Yang, J. C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.121 · Cited by 5 · see citing works
EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?
Atagi, S. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.009 · Cited by 1 · see citing works
Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer
Wang, Y., Wang, F., Zhang, F., Niu, L., Shen, L., Zhu, L., Kang, M., Xie, X., Wang, Y., & Gao, Y. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.02.08 · Cited by 1 · see citing works
Vu, P., & Bazhenova, L. A. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_10
- Authors
- Rudin, C., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D., Schmid, P., Heist, R., Villaflor, V., Sarkar, I., Huseni, M., Foster, P., O'Hear, C., & Gettinger, S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University Hospitals Cleveland Medical Center (US)
- Chinese University of Hong Kong (HK)
- Beth Israel Deaconess Medical Center (US)
- Barts Cancer Institute (GB)
- Massachusetts General Hospital (US)
- Northwestern University (US)
- Genentech (US)
- Yale Cancer Center (US)
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 12
- Issue
- 1
- Pages
- S1302-S1303
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2570717541
- Cited by
- 14
- References
- 0
- Citations by year
- 2022: 1 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 2
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- erlotinib, atezolizumab, EGFR-mutant non-small cell lung cancer, combination therapy, PD-L1 blockade, antitumor immunity, EGFR tyrosine kinase inhibitors, treatment resistance, biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
